Dr. Wang Featured in New Retina Radio Podcast
Texas Retina’s Robert C. Wang, MD, was interviewed about his presentation at the Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting for an episode of the New Retina Radio podcast
read more Dr. Wang Presented Study Results of New Wet AMD Treatment Approach at the ARVO 2025 Meeting
On May 9, 2025, Texas Retina’s Robert C. Wang, MD, presented “Top Line Results from ODYSSEY: A Phase IIb Study of Suprachoroidally Administered CLS-AX in Participants with Neovascular Age-related Macular Degeneration” at
read more
The Ohio State University Recognizes Dr. Wang for Giving Back
In the latest issue of BuckEye Ophthalmology, The Ohio State University Department of Ophthalmology & Visual Sciences featured Texas Retina’s Robert C. Wang, MD, for giving back through the George & Shirley
read more
Dr. Wang Presents to State of Texas Association of Rheumatologists
This past weekend, Texas Retina’s Robert C. Wang presented “Uveitis: Everything Everywhere All at Once” at the State of Texas Association of Rheumatologists (STAR) 2025 Annual Meeting held at the Gaylord Texan
read more
Dr. Wang Discussed CLARITY Clinical Trial Enrollment at Presentation in Miami
Robert Wang, MD, Texas Retina’s Director of Clinical Research for Plano, recently spoke about the CLARITY clinical trial at a meeting of retina specialists held in Miami, Florida. A global, multi-center Phase
read more
Inflammatory Eye Disease Awareness Week
Prevent Blindness has declared September 16–22, 2024, as Inflammatory Eye Disease Awareness Week. There are several inflammatory eye conditions. The one we specialize in at Texas Retina is called uveitis [u-vee-i-tis]. Understanding
read more
Dr. Wang Invited to Serve as Guest Lecturer at Ohio State University
Texas Retina’s Robert C. Wang will speak at The Ohio State University’s 7th Annual Retina Case Forum on Friday, August 16, 2024, as an invited guest lecturer. The event is a case-based
read more
Dr. Wang Presented Initial Study Results of New Non-infectious Uveitis Treatment at ASRS 2024 Annual Meeting
Texas Retina’s Robert C. Wang, MD, presented “Safety and Efficacy of Brepocitinib, a TYK2/JAK1 Inhibitor, in Active Non-Infectious Uveitis: 24-Week Results from a 52-Week Phase II Study (NEPTUNE)” at the 2024 Annual
read more
Inflammatory Eye Disease Awareness Week
Prevent Blindness has declared September 18 – 24, 2023, as Inflammatory Eye Disease Awareness Week. There are a number of inflammatory eye conditions. The one we specialize in at Texas Retina Associates
read more
Dr. Wang Participated in Roundtable Discussion on XIPERE Treatment for Macular Edema Associated with Uveitis
At the most recent American Academy of Ophthalmology (AAO) Annual Meeting in Chicago, Texas Retina Associates’ Robert Wang, MD, participated in a roundtable discussion with seven other retina specialists to share their
read more